Novartis AG Profit Margin

The latest profit margin for NVSEF is 23.09% as of June 2026. That compares with 25.0% in the prior-year period — down 7.6% year over year. That is above the Healthcare sector average of 15.58%. Investors often review this figure alongside Novartis AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVSEF's profit margin moved from 25.0% to 23.09% — a 7.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novartis AG's valuation or profitability profile.

Against Healthcare companies, NVSEF currently prints 23.09% for profit margin, while the sector average sits near 15.58%. That is roughly 48.2% above the sector mean. Large gaps often invite a closer look at Novartis AG's growth, margins, and balance sheet.

Profit Margin shows how effectively Novartis AG converts resources into returns. At 23.09%, NVSEF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 25.0% in the prior-year period — down 7.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NVSEF's profit margin (23.09%), review year-over-year change from 25.0%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.